The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
BSH 2023 | How the concept of fitness in CLL has changed with the introduction of novel targeted agents
Dima El-Sharkawi, MBBS, MA, PhD, MRCP, FRCPath, The Royal Marsden NHS Foundation Trust, Sutton, UK, shares some insights into how the concept of fitness in chronic lymphocytic leukemia (CLL) has changed over the years. Dr El-Sharkawi explains that the use of novel agents, including Bruton’s tyrosine kinase (BTK) inhibitors, has transformed the field and changed the concept of fitness in this disease. This interview took place at the 63rd Annual Scientific Meeting of the British Society for Haematology (BSH) 2023, held in Birmingham, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria: Abbvie; AstraZeneca; Beigene; Gilead, Janssen; Lily; Roche; Takeda
Conference/ Travel support: Abbvie; Novartis; Roche
Ad boards: Abbvie; ASTEX; AstraZeneca; Beigene; Janssen; Kyowa Kiirin
